|
Neuralgia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The expression of chemokines and their receptors, such as CX3CL1/CX3CR1, CCL2/CCR2, CXCL1/CXCR2, CXCL12/CXCR4 and CCL3/CCR5, is altered in the pathological conditions of CIPN, and chemokine receptor antagonists attenuate neuropathic pain behaviour.
|
31490748 |
2020 |
|
Cocaine Dependence
|
0.010 |
Biomarker
|
disease |
BEFREE |
Evidence that CCR5 knockout mice display fewer dopamine neurons, lower striatal dopamine levels, and reduced locomotor activation compared to wild types also suggest a link between CCR5 receptors and cocaine dependence.
|
31557508 |
2020 |
|
Aortic Valve Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, the CCL5-CCR5 axis inhibits androgen/AR signaling as an upstream mediator.
|
30871130 |
2019 |
|
Bipolar Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Likewise, the percentages of CD8+CXCR3+, CD8+CCR3+, and CD8+CCR5+ lymphocytes were similar in patients with BD and controls.
|
30867081 |
2019 |
|
Patent ductus arteriosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
SIGNIFICANCE: We found that iαβTs are a profoundly activated T-cell subset in PDA that slow tumor growth in murine and human models of disease. iαβTs induce a CCR5-dependent immunogenic tumor-associated macrophage program, T-cell activation and expansion, and should be considered as novel targets for immunotherapy.<i>See related commentary by Banerjee et al., p. 1164</i>.<i>This article is highlighted in the In This Issue feature, p. 1143</i>.
|
31266770 |
2019 |
|
Respiratory Syncytial Virus Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
While RSV-inoculated AB mDC responded to secondary IAV inoculation by efficiently upregulating activation markers and cytokine production, IAV-induced CCR5 downregulation was slightly inhibited in cells exhibiting robust RSV infection.
|
31484754 |
2019 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data therefore demonstrate a hitherto unrecognized protective role of CCR5 in sepsis.
|
30724784 |
2019 |
|
Severe Combined Immunodeficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
As determined by plasma viral RNA and peripheral blood mononuclear cells (PBMC) proviral DNA, we show improved suppression of productive HIV infection in human CD34<sup>+</sup> hematopoietic stem cell-engrafted NOD (nonobese diabetic)-SCID (severe combined immunodeficiency)-il2rg<sup>-/-</sup> (NSG) mice by combined treatment with cART and CCR5 targeting drugs, compared with cART alone, as well as an increased preservation of human CD4<sup>+</sup> T cells (defined as CD45<sup>+</sup> CD3<sup>+</sup> CD4<sup>+</sup> cells) and CD4<sup>+</sup>/CD8<sup>+</sup> cell ratios in infected mice.
|
31099257 |
2019 |
|
Cervical Intraepithelial Neoplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The CCR5 promoter polymorphisms were significantly associated with cervical intraepithelial neoplasia by altering the expression of CCR5 on the cell surface in a Chinese Han population.
|
31151412 |
2019 |
|
Lesion of brain
|
0.010 |
Biomarker
|
group |
BEFREE |
Blockade of CCL5 signaling via C-C chemokine receptor type 5 prevented the formation of brain lesions in a mouse model of autoimmune disease.
|
31243152 |
2019 |
|
Renal interstitial fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Besides, their gene expression levels were found significantly positive correlation with the degree of RIF (CD2: P<0.05, r=0.29; CCL5: P<0.05, r=0.31; CCR5: P<0.05, r=0.38).
|
31700890 |
2019 |
|
Dyslipidemias
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The findings of our study suggest that the CCR5-Δ32 polymorphism is associated with elevated plasma lipid levels and the Δ32 allele increases the risk of dyslipidemia in patients with T1D.
|
30420202 |
2019 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data therefore demonstrate a hitherto unrecognized protective role of CCR5 in sepsis.
|
30724784 |
2019 |
|
Malignant neoplasm of colon stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical trials have recently opened targeting CCR5 using a humanized monoclonal antibody (leronlimab) for metastatic triple negative breast cancer (TNBC) or a small molecule inhibitor (maraviroc) for metastatic colon cancer.
|
31747383 |
2019 |
|
Carcinoma breast stage IV
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the effects of targeting CCR5 by its antagonist maraviroc in metastatic breast cancer cells.
|
30456574 |
2019 |
|
Secondary malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
CCR5 patchiness is, therefore, a signature of liver metastases in our cohort (<i>n</i> = 97 specimens) and relates to globally decreased expression intensity, but does not influence the extent of the response to CCR5 inhibitor Maraviroc in patients.
|
31428524 |
2019 |
|
Sleep Apnea, Obstructive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Besides, the expression of CCR5 in monocytes increased along the AHI value especially in severe OSA patients that was statistically significant compared with mild and moderate OSA groups.
|
30778913 |
2019 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
CCR5 is considered a potential therapeutic target in different neurodegenerative disorders.
|
30658114 |
2019 |
|
Malignant Cystosarcoma Phyllodes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The patient-derived xenografts (PDX) of malignant PTs were used to evaluate the therapeutic effect of CCR5 inhibitor.
|
30890553 |
2019 |
|
Refractory cancer
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Clinical resistance to CCR5 antagonists occurs in two phases, competitive and noncompetitive stages.
|
30787151 |
2019 |
|
charmed
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Further, using tissues from the CHARM-03 clinical trial, we found that CCR5<sup>+</sup> T<sub>RM</sub> are preserved in human mucosal tissue during treatment with the CCR5 antagonist Maraviroc.
|
31801887 |
2019 |
|
Inflammatory disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
CCR5 antagonists can reduce inflammatory disease processes, which has led to an increased interest in using CCR5 antagonists in a wide range of inflammation-driven diseases.
|
31801887 |
2019 |
|
Latent Tuberculosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, CCR5 levels were significantly lower in the LTBI-S group compared with both NIC-NS and NIC-S groups.
|
31141056 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
The potential molecular mechanisms of CCR5, CC6 and CCR9 in PDAC include its intersection of the P53, nuclear factor (NF)‑κB, generic transcription, mitogen‑activated protein kinase and STAT signaling pathways.
|
31432181 |
2019 |
|
Tubulointerstitial fibrosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Besides, their gene expression levels were found significantly positive correlation with the degree of RIF (CD2: P<0.05, r=0.29; CCL5: P<0.05, r=0.31; CCR5: P<0.05, r=0.38).
|
31700890 |
2019 |